Brimonidine Tartrate (UK 14304; AGN190342)

Description: Brimonidine Tartrate (AGN-190342; UK14304; UK-14304; Alphagan), the tartrate salt of Brimonidine, is a highly potent and selective alpha-adrenergic receptor agonist with anti-hypertensive effects. It activates the alpha2A adrenoreceptor with an EC50 of 0.45 nM. Brimonidine was approved to treat open-angle glaucoma or ocular hypertension. Brimonidine reduces the progressive loss of ganglion cells to 26% and 15% at doses of 0.5 mg/kg and 1 mg/kg, respectively. Brimonidine administration initiates 10 days after IOP elevation prevents any further loss of ganglion cells. Brimonidine attenuates the increase in immunoreactivity of GFAP in ocular hypertensive retinas.

References: Invest Ophthalmol Vis Sci. 2001 Nov; 42(12):2849-55; Brain Res. 2001 Sep 21; 913(2):133-9.

Related CAS#: 59803-98-4 (free base); 70359-46-5 (tartrate)